References/Publications for ELISA of Bet v 1

Check all              

Select PubMed ID Description
7530747 J Immunol. 1995 Feb 15;154(4):1932-40.

Nonallergic individuals recognize the same T cell epitopes of Bet v 1, the major
birch pollen allergen, as atopic patients.

Ebner C(1), Schenk S, Najafian N, Siemann U, Steiner R, Fischer GW, Hoffmann K,
Szépfalusi Z, Scheiner O, Kraft D.


7549498 Int Arch Allergy Immunol. 1995 Oct;108(2):119-26.

Purification and characterization of the major allergen from apple and its
allergenic cross-reactivity with Bet v 1.

Fahlbusch B(1), Rudeschko O, Müller WD, Schlenvoigt G, Vettermann S, Jäger L.


8366100 J Biol Chem. 1993 Sep 15;268(26):19574-80.

Purification and characterization of recombinant Bet v I, the major birch pollen
allergen. Immunological equivalence to natural Bet v I.

Ferreira FD(1), Hoffmann-Sommergruber K, Breiteneder H, Pettenburger K, Ebner C,
Sommergruber W, Steiner R, Bohle B, Sperr WR, Valent P, et al.


8626988 J Allergy Clin Immunol. 1996 May;97(5):1100-9.

Skin testing with recombinant allergens rBet v 1 and birch profilin, rBet v 2:
diagnostic value for birch pollen and associated allergies.

Pauli G(1), Oster JP, Deviller P, Heiss S, Bessot JC, Susani M, Ferreira F, Kraft
D, Valenta R.


8789543 Clin Exp Allergy. 1996 Jan;26(1):50-60.

Serological and skin-test diagnosis of birch pollen allergy with recombinant Bet
v I, the major birch pollen allergen.

Menz G(1), Dolecek C, Schönheit-Kenn U, Ferreira F, Moser M, Schneider T, Suter
M, Boltz-Nitulescu G, Ebner C, Kraft D, Valenta R.


8768804 Int Arch Allergy Immunol. 1996 Aug;110(4):364-70.

Direct determination of allergens in ambient aerosols: methodological aspects.

Schäppi GF(1), Monn C, Wüthrich B, Wanner HU.


8939154 J Allergy Clin Immunol. 1996 Nov;98(5 Pt 1):913-21.

Induction of IgE antibodies in mice and rhesus monkeys with recombinant birch
pollen allergens: different allergenicity of Bet v 1 and Bet v 2.

Vrtala S(1), Mayer P, Ferreira F, Susani M, Sehon AH, Kraft D, Valenta R.


9011868 Pneumologie. 1996 Sep;50(9):632-40.

[Serologic and skin test diagnosis of birch pollen allergy with recombinant Bet v
1, the chief allergen of birch].

[Article in German]

Menz G(1), Dolecek C, Schönheit-Kenn U, Ferreira F, Moser M, Schneider T, Suter
M, Boltz-Nitulescu G, Ebner C, Kraft D, Valenta R.


9116499 Protein Expr Purif. 1997 Feb;9(1):33-9.

High-level expression and purification of the major birch pollen allergen, Bet v


Hoffmann-Sommergruber K(1), Susani M, Ferreira F, Jertschin P, Ahorn H, Steiner
R, Kraft D, Scheiner O, Breiteneder H.


9130538 Int Arch Allergy Immunol. 1997 May-Jul;113(1-3):252-4.

A sensitive ELISA to detect IgG subclass antibodies to Bet v 1 in infants.

Jenmalm MC(1).


9291291 Clin Exp Allergy. 1997 Aug;27(8):926-31.

Quantification in mass units of Bet v 1, the main allergen of Betula verrucosa
pollen, by a monoclonal antibody based-ELISA.

Ramírez J(1), Carpizo JA, Ipsen H, Carreira J, Lombardero M.


9389296 J Allergy Clin Immunol. 1997 Nov;100(5):656-61.

Concentrations of the major birch tree allergen Bet v 1 in pollen and respirable
fine particles in the atmosphere.

Schäppi GF(1), Suphioglu C, Taylor PE, Knox RB.


9338612 Int Arch Allergy Immunol. 1997 Oct;114(2):175-84.

Maternal influence on IgG subclass antibodies to Bet v 1 during the first 18
months of life as detected with a sensitive ELISA.

Jenmalm MC(1), Holt PG, Björkstén B.


9893193 J Allergy Clin Immunol. 1999 Jan;103(1 Pt 1):107-13.

Immune responses after immunization with plasmid DNA encoding Bet v 1, the major
allergen of birch pollen.

Hartl A(1), Kiesslich J, Weiss R, Bernhaupt A, Mostböck S, Scheiblhofer S, Ebner
C, Ferreira F, Thalhamer J.


9837853 FASEB J. 1998 Dec;12(15):1635-42.

Peptide mimotopes displayed by phage inhibit antibody binding to bet v 1, the
major birch pollen allergen, and induce specific IgG response in mice.

Jensen-jarolim E(1), Leitner A, Kalchhauser H, Zürcher A, Ganglberger E, Bohle B,
Scheiner O, Boltz-nitulescu G, Breiteneder H.


10380779 Allergy. 1999 May;54(5):478-83.

Immunologic significance of respirable atmospheric starch granules containing
major birch allergen Bet v 1.

Schäppi GF(1), Taylor PE, Staff IA, Rolland JM, Suphioglu C.


10550741 J Allergy Clin Immunol. 1999 Nov;104(5):969-77.

Skin test evaluation of genetically engineered hypoallergenic derivatives of the
major birch pollen allergen, Bet v 1: results obtained with a mix of two
recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish
population before the birch pollen season.

van Hage-Hamsten M(1), Kronqvist M, Zetterström O, Johansson E, Niederberger V,
Vrtala S, Grönlund H, Grönneberg R, Valenta R.


10722049 Biol Chem. 2000 Jan;381(1):39-47.

Engineering, purification and applications of His-tagged recombinant antibody
fragments with specificity for the major birch pollen allergen, bet v1.

Flicker S(1), Laffer S, Steinberger P, Alhani B, Zhu Y, Laukkanen ML, Keinänen K,
Kraft D, Valenta R.


10877820 FASEB J. 2000 Jul;14(10):1279-88.

Rapid production of the major birch pollen allergen Bet v 1 in Nicotiana
benthamiana plants and its immunological in vitro and in vivo characterization.

Krebitz M(1), Wiedermann U, Essl D, Steinkellner H, Wagner B, Turpen TH, Ebner C,
Scheiner O, Breiteneder H.


10931114 Clin Exp Allergy. 2000 Aug;30(8):1076-84.

Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with
rBet v 1 wild-type by skin prick and intradermal testing: results obtained in a
French population.

Pauli G(1), Purohit A, Oster JP, De Blay F, Vrtala S, Niederberger V, Kraft D,
Valenta R.


11307030 Int Arch Allergy Immunol. 2001 Jan-Mar;124(1-3):406-10.

The influence of CpG motifs on a protein or DNA-based Th2-type immune response
against major pollen allergens Bet v 1a, Phl p 2 and Escherichia coli-derived
beta-galactosidase.

Hochreiter R(1), Hartl A, Freund J, Valenta R, Ferreira F, Thalhamer J.


12569978 Clin Exp Allergy. 2002 Nov;32(11):1583-8.

Phage-displayed Bet mim 1, a mimotope of the major birch pollen allergen Bet v 1,
induces B cell responses to the natural antigen using bystander T cell help.

Schöll I(1), Wiedermann U, Förster-Waldl E, Ganglberger E, Baier K,
Boltz-Nitulescu G, Scheiner O, Ebner C, Jensen-Jarolim E.


14720271 Clin Exp Allergy. 2004 Jan;34(1):115-22.

Vaccines for birch pollen allergy based on genetically engineered hypoallergenic
derivatives of the major birch pollen allergen, Bet v 1.

Mahler V(1), Vrtala S, Kuss O, Diepgen TL, Suck R, Cromwell O, Fiebig H, Hartl A,
Thalhamer J, Schuler G, Kraft D, Valenta R.


16008686 Clin Exp Allergy. 2005 Jul;35(7):970-8.

Component-resolved in vitro diagnosis in carrot allergy: does the use of
recombinant carrot allergens improve the reliability of the diagnostic procedure?

Ballmer-Weber BK(1), Wangorsch A, Bohle B, Kaul S, Kündig T, Fötisch K, van Ree
R, Vieths S.


17267036 Mol Immunol. 2007 Apr;44(10):2518-27. Epub 2007 Jan 30.

Mutational epitope analysis and cross-reactivity of two isoforms of Api g 1, the
major celery allergen.

Wangorsch A(1), Ballmer-Weber BK, Rösch P, Holzhauser T, Vieths S.


17848805 Int Arch Allergy Immunol. 2008;145(2):122-30. Epub 2007 Sep 10.

Year-to-year variation in release of Bet v 1 allergen from birch pollen: evidence
for geographical differences between West and South Germany.

Buters JT(1), Kasche A, Weichenmeier I, Schober W, Klaus S, Traidl-Hoffmann C,
Menzel A, Huss-Marp J, Kramer U, Behrendt H.


17889932 J Allergy Clin Immunol. 2008 Jan;121(1):246-52. Epub 2007 Sep 24.

Naturally occurring hypoallergenic Bet v 1 isoforms fail to induce IgE responses
in individuals with birch pollen allergy.

Wagner S(1), Radauer C, Bublin M, Hoffmann-Sommergruber K, Kopp T, Greisenegger
EK, Vogel L, Vieths S, Scheiner O, Breiteneder H.


17911617 J Immunol. 2007 Oct 15;179(8):5309-16.

Analysis of epitope-specific immune responses induced by vaccination with
structurally folded and unfolded recombinant Bet v 1 allergen derivatives in man.

Pree I(1), Reisinger J, Focke M, Vrtala S, Pauli G, van Hage M, Cromwell O,
Gadermaier E, Egger C, Reider N, Horak F, Valenta R, Niederberger V.


17912007 Int Arch Allergy Immunol. 2008;145(3):193-206. Epub 2007 Oct 2.

Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate
for allergen-specific immunotherapy.

Kahlert H(1), Suck R, Weber B, Nandy A, Wald M, Keller W, Cromwell O, Fiebig H.


17979095 Mol Nutr Food Res. 2007 Dec;51(12):1527-36.

Purification and characterization of natural Bet v 1 from birch pollen and
related allergens from carrot and celery.

Bollen MA(1), Garcia A, Cordewener JH, Wichers HJ, Helsper JP, Savelkoul HF, van
Boekel MA.


18070167 Clin Exp Allergy. 2008 Feb;38(2):365-73. Epub 2007 Dec 7.

Molecular characterization of a human immunoglobulin G4 antibody specific for the
major birch pollen allergen, Bet v 1.

Flicker S(1), Steinberger P, Eibensteiner PB, Lebecque S, Kraft D, Valenta R.


19183416 Allergy. 2009 Jul;64(7):1038-45. doi: 10.1111/j.1398-9995.2009.01957.x. Epub 2009
Jan 31.

Standardization of allergen products: 1. Detailed characterization of
GMP-produced recombinant Bet v 1.0101 as biological reference preparation.

Himly M(1), Nony E, Chabre H, Van Overtvelt L, Neubauer A, van Ree R, Buchheit
KH, Vieths S, Moingeon P, Ferreira F.


20132158 Allergy. 2010 Jul;65(7):850-8. doi: 10.1111/j.1398-9995.2009.02286.x. Epub 2010
Feb 4.

The allergen Bet v 1 in fractions of ambient air deviates from birch pollen
counts.

Buters JT(1), Weichenmeier I, Ochs S, Pusch G, Kreyling W, Boere AJ, Schober W,
Behrendt H.


21093057 Mol Immunol. 2011 Jan;48(4):431-41. doi: 10.1016/j.molimm.2010.09.016. Epub 2010
Nov 18.

Altered IgE epitope presentation: A model for hypoallergenic activity revealed
for Bet v 1 trimer.

Campana R(1), Vrtala S, Maderegger B, Dall'Antonia Y, Zafred D, Blatt K, Herrmann
H, Focke-Tejkl M, Swoboda I, Scheiblhofer S, Gieras A, Neubauer A, Keller W,
Valent P, Thalhamer J, Spitzauer S, Valenta R.


21215346 Vaccine. 2011 Mar 3;29(11):2140-8. doi: 10.1016/j.vaccine.2010.12.080. Epub 2011
Jan 5.

Genetic engineering of trimers of hypoallergenic fragments of the major birch
pollen allergen, Bet v 1, for allergy vaccination.

Vrtala S(1), Fohr M, Campana R, Baumgartner C, Valent P, Valenta R.


21451110 J Immunol. 2011 May 1;186(9):5333-44. doi: 10.4049/jimmunol.1000804. Epub 2011
Mar 30.

Mapping of conformational IgE epitopes with peptide-specific monoclonal
antibodies reveals simultaneous binding of different IgE antibodies to a surface
patch on the major birch pollen allergen, Bet v 1.

Gieras A(1), Cejka P, Blatt K, Focke-Tejkl M, Linhart B, Flicker S, Stoecklinger
A, Marth K, Drescher A, Thalhamer J, Valent P, Majdic O, Valenta R.


23182706 Immunobiology. 2013 Jun;218(6):884-91. doi: 10.1016/j.imbio.2012.10.008. Epub
2012 Oct 26.

Passive immunization with allergen-specific IgG antibodies for treatment and
prevention of allergy.

Flicker S(1), Linhart B, Wild C, Wiedermann U, Valenta R.


23327896 Pharmeur Bio Sci Notes. 2012 Apr;2012:118-34.

Establishment of recombinant major allergens Bet v 1 and Phl p 5a as Ph. Eur.
reference standards and validation of ELISA methods for their measurement.
Results from feasibility studies.

Vieths S(1), Barber D, Chapman M, Costanzo A, Daas A, Fiebig H, Hanschmann KM,
Hrabina M, Kaul S, Ledesma A, Moingeon P, Reese G, Schörner C, van Ree R, Weber
B, Buchheit KH.


23498592 J Allergy Clin Immunol. 2013 Jun;131(6):1711-3. doi: 10.1016/j.jaci.2012.12.1577.
Epub 2013 Mar 14.

Identification of allergen-resolved threshold doses of carrot (Daucus carota) by
means of oral challenge and ELISA.

Foetisch K, Scheurer S, Vieths S, Hanschmann KM, Lidholm J, Mahler V.

DOI: 10.1016/j.jaci.2012.12.1577
PMID: 23498592 [Indexed for MEDLINE]
23998344
Allergy. 2013 Sep;68(9):1199-202. doi: 10.1111/all.12204. Epub 2013 Sep 3.

An assay that may predict the development of IgG enhancing allergen-specific IgE
binding during birch immunotherapy.

Selb R(1), Eckl-Dorna J, Vrtala S, Valenta R, Niederberger V.


--DOI:10.1186/2045-7022-3-S3-O15
24447086 Clin Exp Allergy. 2014 Feb;44(2):278-87. doi: 10.1111/cea.12216.

Prophylactic and therapeutic vaccination with carrier-bound Bet v 1 peptides
lacking allergen-specific T cell epitopes reduces Bet v 1-specific T cell
responses via blocking antibodies in a murine model for birch pollen allergy.

Linhart B(1), Narayanan M, Focke-Tejkl M, Wrba F, Vrtala S, Valenta R.


24447087 Clin Exp Allergy. 2014 Feb;44(2):288-99. doi: 10.1111/cea.12230.

Human IgE against the major allergen Bet v 1--defining an epitope with limited
cross-reactivity between different PR-10 family proteins.

Levin M(1), Davies AM, Liljekvist M, Carlsson F, Gould HJ, Sutton BJ, Ohlin M.


24529686 J Allergy Clin Immunol. 2014 Jul;134(1):188-94. doi: 10.1016/j.jaci.2013.12.1073.
Epub 2014 Feb 12.

Chimeras of Bet v 1 and Api g 1 reveal heterogeneous IgE responses in patients
with birch pollen allergy.

Gepp B(1), Lengger N(1), Bublin M(1), Hemmer W(2), Breiteneder H(3), Radauer
C(1).


25327982 Allergy. 2015 Jan;70(1):59-66. doi: 10.1111/all.12534. Epub 2014 Nov 30.

IgE, IgG4 and IgA specific to Bet v 1-related food allergens do not predict oral
allergy syndrome.

Guhsl EE(1), Hofstetter G, Lengger N, Hemmer W, Ebner C, Fröschl R, Bublin M,
Lupinek C, Breiteneder H, Radauer C.


25635684 PLoS One. 2015 Jan 30;10(1):e0117904. doi: 10.1371/journal.pone.0117904.
eCollection 2015.

The major birch pollen allergen Bet v 1 induces different responses in dendritic
cells of birch pollen allergic and healthy individuals.

Smole U(1), Radauer C(2), Lengger N(2), Svoboda M(2), Rigby N(3), Bublin M(2),
Gaier S(2), Hoffmann-Sommergruber K(2), Jensen-Jarolim E(4), Mechtcheriakova
D(2), Breiteneder H(2).


26042900 PLoS One. 2015 Jun 4;10(6):e0128677. doi: 10.1371/journal.pone.0128677.
eCollection 2015.

Ligand Recognition of the Major Birch Pollen Allergen Bet v 1 is Isoform
Dependent.

Seutter von Loetzen C(1), Jacob T(1), Hartl-Spiegelhauer O(1), Vogel L(2),
Schiller D(2), Spörlein-Güttler C(3), Schobert R(3), Vieths S(2), Hartl MJ(1),
Rösch P(1).


26304061 Allergy. 2015 Dec;70(12):1559-68. doi: 10.1111/all.12732. Epub 2015 Sep 25.

Epicutaneous immunotherapy with a hypoallergenic Bet v 1 suppresses allergic
asthma in a murine model.

Siebeneicher S(1), Reuter S(2)(3), Wangorsch A(4), Krause M(1)(4), Foetisch K(5),
Heinz A(2), Naito S(6), Reuter A(5), Taube C(7), Vieths S(4)(5), Scheurer
S(4)(5), Toda M(1)(4).


27018782 Allergy. 2016 Oct;71(10):1414-24. doi: 10.1111/all.12898. Epub 2016 Apr 28.

Standardization of allergen products: 3. Validation of candidate European
Pharmacopoeia standard methods for quantification of major birch allergen Bet v


Kaul S(1), Zimmer J(1), Dehus O(1), Costanzo A(2), Daas A(2), Buchheit KH(2),
Asturias JA(3), Barber D(4), Carnés J(5), Chapman M(6), Dayan-Kenigsberg J(7),
Döring S(1), Führer F(1), Hanschmann KM(1), Holzhauser T(1), Ledesma A(4),
Moingeon P(8), Nony E(8), Pini C(9), Plunkett G(10), Reese G(11), Sandberg E(12),
Sander I(13), Strecker D(1), Valerio C(14), van Ree R(15), Vieths S(16).


27770477 Clin Exp Allergy. 2017 May;47(5):693-703. doi: 10.1111/cea.12835. Epub 2016 Nov


IgE and allergen-specific immunotherapy-induced IgG4 recognize similar epitopes
of Bet v 1, the major allergen of birch pollen.

Groh N(1), von Loetzen CS(2), Subbarayal B(3), Möbs C(4), Vogel L(1), Hoffmann
A(1), Fötisch K(1), Koutsouridou A(1), Randow S(1), Völker E(1), Seutter von
Loetzen A(1), Rösch P(2), Vieths S(1), Pfützner W(4), Bohle B(3), Schiller D(1).


28070926 Mol Nutr Food Res. 2017 Apr;61(4). doi: 10.1002/mnfr.201600902. Epub 2017 Feb 10.

Identification and implication of an allergenic PR-10 protein from walnut in
birch pollen associated walnut allergy.

Wangorsch A(1), Jamin A(1), Lidholm J(2), Gräni N(3), Lang C(3), Ballmer-Weber
B(3)(4), Vieths S(1), Scheurer S(1).


28456624 J Allergy Clin Immunol. 2018 Jan;141(1):293-299.e6. doi:
1016/j.jaci.2017.02.044. Epub 2017 Apr 26.

Fusion proteins of flagellin and the major birch pollen allergen Bet v 1 show
enhanced immunogenicity, reduced allergenicity, and intrinsic adjuvanticity.

Kitzmüller C(1), Kalser J(1), Mutschlechner S(1), Hauser M(2), Zlabinger GJ(3),
Ferreira F(2), Bohle B(4).


28494467 Int Arch Allergy Immunol. 2017;173(1):44-50. doi: 10.1159/000471852. Epub 2017
May 12.

Expression and Characterization of Functional Recombinant Bet v 1.0101 in the
Chloroplast of Chlamydomonas reinhardtii.

Hirschl S(1), Ralser C, Asam C, Gangitano A, Huber S, Ebner C, Bohle B, Wolf M,
Briza P, Ferreira F, Griesbeck C, Wallner M.


29065418 Int Arch Allergy Immunol. 2017;174(2):77-85. doi: 10.1159/000481092. Epub 2017
Oct 25.

Characterization of a Major Allergen from Mongolian Oak, Quercus mongolica, a
Dominant Species of Oak in Korea.

Lee JY(1), Yang M, Jeong KY, Sim DW, Park JH, Park KH, Lee JH, Park JW.


29143737 Pharmeur Bio Sci Notes. 2017;2017:69-87.

Validation of ELISA methods for quantification of the major birch allergen Bet v
1 (BSP090).

Kaul S(1), Zimmer J(1), Dehus O(1), Constanzo A(2), Daas A(2), Buchheit KH(2),
Asturias J(3), Arilla MC(3), Barber D(4), Bertocchi A(5), Brunetto B(6), Carnes
JA(7), Chapman M(8), Chaudemanche G(5), Dayan-Kenigsberg J(5), Döring S(1),
Führer F(1), Gallego MT(7), Iacovacci P(6), Hanschmann KM(1), Holzhauser T(1),
Hrabina M(9), Ledesma A(4), Moingeon P(9), Nony E(9), Pini C(6), Plunkett G(10),
Raulf M(11), Reese G(12), Sandberg E(13), Sander I(11), Smith B(8), Strecker
D(1), Valerio C(14), van Ree R(15), Weber B(12), Vieths S(1).


29171882 Allergy. 2018 May;73(5):1032-1040. doi: 10.1111/all.13364. Epub 2017 Dec 12.

Characterization of epitope specificities of reference antibodies used for the
quantification of the birch pollen allergen Bet v 1.

Brier S(1), Le Mignon M(1), Jain K(1), Lebrun C(1), Peurois F(1), Kellenberger
C(2), Bordas-Le Floch V(1), Mascarell L(1), Nony E(1), Moingeon P(1).


29315611 Allergy. 2018 Jul;73(7):1425-1435. doi: 10.1111/all.13394. Epub 2018 Feb 20.

Isolation of a high-affinity Bet v 1-specific IgG-derived ScFv from a subject
vaccinated with hypoallergenic Bet v 1 fragments.

Gadermaier E(1), Marth K(1), Lupinek C(1), Campana R(1), Hofer G(2), Blatt K(3),
Smiljkovic D(3), Roder U(4), Focke-Tejkl M(1), Vrtala S(1), Keller W(2), Valent
P(3), Valenta R(1)(5), Flicker S(1).


29940558 Int Arch Allergy Immunol. 2018;177(2):116-122. doi: 10.1159/000489707. Epub 2018
Jun 25.

Harmonization of the Genetic Code Effectively Enhances the Recombinant Production
of the Major Birch Pollen Allergen Bet v 1.

Asam C(1), Roulias A(1), Parigiani MA(1), Haab A(1), Wallner M(1), Wolf M(1),
Briza P(1), Bohle B(2), Ferreira F(1), Hauser M(1).


30170487 Anal Chem. 2018 Oct 2;90(19):11315-11323. doi: 10.1021/acs.analchem.8b01864. Epub
2018 Sep 14.

Epitope Mapping by HDX-MS Elucidates the Surface Coverage of Antigens Associated
with High Blocking Efficiency of Antibodies to Birch Pollen Allergen.

Zhang Q(1), Yang J(1), Bautista J(1), Badithe A(1), Olson W(1), Liu Y(1).


30471304 J Allergy Clin Immunol. 2019 Mar;143(3):1258-1261. doi:
1016/j.jaci.2018.11.011. Epub 2018 Nov 22.

Vaccination of nonallergic individuals with recombinant hypoallergenic fragments
of birch pollen allergen Bet v 1: Safety, effects, and mechanisms.

Campana R(1), Marth K(1), Zieglmayer P(2), Weber M(1), Lupinek C(1), Zhernov
Y(3), Elisyutina O(3), Khaitov M(3), Rigler E(1), Westritschnig K(1), Berger
U(4), Wolkersdorfer M(5), Horak F Jr(6), Horak F(7), Valenta R(8).


30850635 Sci Rep. 2019 Mar 8;9(1):4006. doi: 10.1038/s41598-019-39798-8.

Fusion proteins consisting of Bet v 1 and Phl p 5 form IgE-reactive aggregates
with reduced allergenic activity.

Najafi N(1), Hofer G(2), Gattinger P(1), Smiljkovic D(3), Blatt K(3), Selb R(4),
Stoecklinger A(5), Keller W(2), Valent P(3), Niederberger V(4), Thalhamer J(5),
Valenta R(1)(6)(7), Flicker S(8).


30852210 Sci Total Environ. 2019 Jun 10;668:333-341. doi: 10.1016/j.scitotenv.2019.02.345.
Epub 2019 Feb 27.

Assessment of the potential real pollen related allergenic load on the atmosphere
of Porto city.

Fernández-González M(1), Ribeiro H(2), Pereira JRS(3), Rodríguez-Rajo FJ(4),
Abreu I(3).


31771108 Foods. 2019 Nov 22;8(12). pii: E609. doi: 10.3390/foods8120609.

Purification and Characterization of Pathogenesis Related Class 10 Panallergens.

McBride JK(1), Cheng H(1), Maleki SJ(1), Hurlburt BK(1).


32259540 J Allergy Clin Immunol. 2020 Oct;146(4):894-900.e2. doi:
1016/j.jaci.2020.03.015. Epub 2020 Apr 4.

IgE-blocking antibodies following SLIT with recombinant Mal d 1 accord with
improved apple allergy.

Sánchez Acosta G(1), Kinaciyan T(2), Kitzmüller C(1), Möbs C(3), Pfützner W(3),
Bohle B(4).


32300351
Front Plant Sci. 2020 Apr 2;11:344. doi: 10.3389/fpls.2020.00344. eCollection


High-Yield Production of the Major Birch Pollen Allergen Bet v 1 With Allergen
Immunogenicity in Nicotiana benthamiana.

Yamada Y(1), Kidoguchi M(2)(3), Yata A(1), Nakamura T(2), Yoshida H(1)(4), Kato
Y(3), Masuko H(5), Hizawa N(5), Fujieda S(3), Noguchi E(2), Miura K(1)(4).


32615568 Int Arch Allergy Immunol. 2020;181(9):675-679. doi: 10.1159/000508694. Epub 2020
Jul 2.

Effects of Mechanical Drying on the Removal of Pollen Allergens.

Choi YJ(1), Park J(2), Seong S(3), Oh JW(4).


32784509 Int J Mol Sci. 2020 Aug 8;21(16). pii: E5693. doi: 10.3390/ijms21165693.

Filling the Antibody Pipeline in Allergy: PIPE Cloning of IgE, IgG1 and IgG4
against the Major Birch Pollen Allergen Bet v 1.

Köhler VK(1)(2), Crescioli S(3)(4), Fazekas-Singer J(1)(2), Bax HJ(3)(5), Hofer
G(6), Pranger CL(1)(2), Hufnagl K(1)(2), Bianchini R(1)(2), Flicker S(2), Keller
W(6), Karagiannis SN(3)(4)(7), Jensen-Jarolim E(1)(2).


33013894 Front Immunol. 2020 Sep 3;11:2118. doi: 10.3389/fimmu.2020.02118. eCollection


In vivo Induction of Functional Inhibitory IgG Antibodies by a Hypoallergenic Bet
v 1 Variant.

Aglas L(1), Bethanis A(1), Chrusciel P(2), Stolz F(3), Gruen M(1), Jaakkola
UM(2), Jongejan L(4), Yatkin E(2), Van Ree R(4).


33070421 Clin Exp Allergy. 2021 Feb;51(2):253-261. doi: 10.1111/cea.13764. Epub 2021 Jan


Allergenicity at component level of sub-pollen particles from different sources
obtained by osmolar shock: A molecular approach to thunderstorm-related asthma
outbreaks.

Cecchi L(1)(2), Scala E(3), Caronni S(4), Citterio S(4), Asero R(5).


33724487 Allergy. 2021 Aug;76(8):2555-2564. doi: 10.1111/all.14817. Epub 2021 May 6.

IgE-cross-blocking antibodies to Fagales following sublingual immunotherapy with
recombinant Bet v 1.

Grilo JR(1), Kitzmüller C(1), Aglas L(2), Sánchez Acosta G(1), Vollmann U(1),
Ebner C(3), Horak F(4), Kinaciyan T(5), Radauer C(1), Ferreira F(2), Jahn-Schmid
B(1), Bohle B(1).


33765259 Environ Sci Pollut Res Int. 2021 Aug;28(29):39952-39965. doi:
1007/s11356-021-13483-8. Epub 2021 Mar 25.

Changes in qualitative and quantitative traits of birch (Betula pendula) pollen
allergenic proteins in relation to the pollution contamination.

Ziemianin M(1), Waga J(2), Czarnobilska E(1), Myszkowska D(3).


34126155 J Allergy Clin Immunol. 2022 Jan;149(1):200-211. doi: 10.1016/j.jaci.2021.05.038.
Epub 2021 Jun 11.

Targeting immunodominant Bet v 1 epitopes with monoclonal antibodies prevents the
birch allergic response.

Atanasio A(1), Franklin MC(1), Kamat V(1), Hernandez AR(1), Badithe A(1), Ben
LH(1), Jones J(1), Bautista J(1), Yancopoulos GD(1), Olson W(1), Murphy AJ(1),
Sleeman MA(1), Orengo JM(2).


34740603 J Allergy Clin Immunol. 2021 Nov 2. pii: S0091-6749(21)01684-5. doi:
1016/j.jaci.2021.10.026. [Epub ahead of print]

Isotype-specific binding patterns of serum antibodies to multiple conformational
epitopes of Bet v 1.

Schmalz S(1), Mayr V(1), Shosherova A(1), Gepp B(2), Ackerbauer D(1), Sturm G(3),
Bohle B(1), Breiteneder H(1), Radauer C(4).


34795666 Front Immunol. 2021 Oct 26;12:744544. doi: 10.3389/fimmu.2021.744544. eCollection


Preventive Administration of Non-Allergenic Bet v 1 Peptides Reduces Allergic
Sensitization to Major Birch Pollen Allergen, Bet v 1.

Akinfenwa O(1), Huang HJ(1), Linhart B(1), Focke-Tejkl M(1)(2), Vrtala S(1),
Poroshina A(3), Nikonova A(3), Khaitov M(3)(4), Campion NJ(5), Eckl-Dorna J(5),
Niederberger-Leppin V(5), Kratzer B(6), Tauber PA(6), Pickl WF(2)(6), Kundi M(7),
Campana R(1), Valenta R(1)(2)(3)(8).


34837242 Allergy. 2021 Nov 27. doi: 10.1111/all.15191. [Epub ahead of print]

Isolation of nanobodies with potential to reduce patients' IgE binding to Bet v


Zettl I(1), Ivanova T(2), Strobl MR(3), Weichwald C(1), Goryainova O(2), Khan
E(2), Rutovskaya MV(2)(4), Focke-Tejkl M(1), Drescher A(5), Bohle B(3), Flicker
S(1), Tillib SV(2).